Genzyme Seprafilm approval will allow broader use than panel recommendation, company exec says.
This article was originally published in The Gray Sheet
Executive SummaryGENZYME SEPRAFILM APPROVAL WILL BE BROADER THAN PANEL RECOMMENDATION for the post-operative adhesion reduction product, the firm says. Speaking at a June 25 meeting of the Food and Drug Law Institute in Washington, D.C., Genzyme VP, Clinical, Medical and Regulatory Affairs Richard Moscicki, MD, said the company has "worked very successfully with the FDA reviewers -- despite working within the restraints of the advisory panel -- to develop a very broad, appropriate label for the use of Seprafilm" during open abdominal surgery.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.